Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 7;11(12):2280-2287.
doi: 10.2215/CJN.02920316. Epub 2016 Aug 15.

Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance

Affiliations

Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance

Mitchell H Rosner et al. Clin J Am Soc Nephrol. .

Abstract

Paraprotein-related kidney disease represents a complex group of diseases caused by an abnormal paraprotein secreted by a clone of B cells. The disease manifestations range from tubulopathies, such as the Fanconi syndrome, to a spectrum of glomerular diseases that can present with varying degrees of proteinuria and renal dysfunction. Diagnosis of these diseases can be challenging because of the wide range of manifestations as well as the relatively common finding of a serum paraprotein, especially in elderly patients. Thus, renal biopsy along with detailed hematologic workup is essential to link the presence of the paraprotein to the associated renal disease. Recent advances in treatment with more effective and targeted chemotherapies, as well as stem cell transplantation, have improved the renal and overall prognosis for many of these disorders.

Keywords: Aged; B-Lymphocytes; Biopsy; Fanconi Syndrome; Humans; Kidney Diseases; Paraproteins; Prognosis; Stem Cell Transplantation; kidney; kidney disease; monoclonal gammopathy; multiple myeloma; paraproteinemia; proteinuria.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagnostic evaluation of paraprotein–related kidney disease. *Lymph node biopsy may be indicated if bone marrow aspirate/biopsy is negative and suspicion for lymphoma is high, especially if a monoclonal IgM is present.

Similar articles

Cited by

References

    1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21–33, 2003 - PubMed
    1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354: 1362–1369, 2006 - PubMed
    1. Richardson PG, Laubach J, Paba-Prada C, Anderson KC: IgD and IgE variants of myeloma: Valuable insights and therapeutic opportunities. Oncology (Williston Park) 27: 803–804, 2013 - PubMed
    1. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. Lancet 375: 1721–1728, 2010 - PMC - PubMed
    1. Eisele L, Dürig J, Hüttmann A, Dührsen U, Assert R, Bokhof B, Erbel R, Mann K, Jöckel KH, Moebus S; Heinz Nixdorf Recall Study Investigative Group: Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol 91: 243–248, 2012 - PubMed

Publication types

MeSH terms